Tucatinib Intermediates: The Backbone of Advanced Oncology APIs
In the ever-evolving landscape of cancer treatment, Tucatinib has emerged as a breakthrough therapeutic agent, particularly in managing HER2-positive breast cancer. The growing demand for this targeted therapy has, in turn, led to an increased focus on the Tucatinib intermediates—the crucial building blocks involved in the drug’s synthesis. What Are Tucatinib Intermediates? Tucatinib intermediates are […]
Continue Reading